BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36. [PMID: 17208639 DOI: 10.1016/s0140-6736(07)60028-2] [Cited by in Crossref: 1059] [Cited by in F6Publishing: 345] [Article Influence: 70.6] [Reference Citation Analysis]
Number Citing Articles
1 Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M. PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ Breast Cancer 2022;8:87. [PMID: 35859079 DOI: 10.1038/s41523-022-00452-8] [Reference Citation Analysis]
2 Konishi T, Fujiogi M, Michihata N, Ohbe H, Matsui H, Fushimi K, Tanabe M, Seto Y, Yasunaga H. Cost-effectiveness analysis of trastuzumab monotherapy versus adjuvant chemotherapy plus trastuzumab in elderly patients with HER2-positive early breast cancer. Jpn J Clin Oncol 2022:hyac107. [PMID: 35775313 DOI: 10.1093/jjco/hyac107] [Reference Citation Analysis]
3 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
4 Tavberidze N, Zhang W. HER2 (ERBB2) alterations in colorectal cancers. Human Pathology Reports 2022;28:300628. [DOI: 10.1016/j.hpr.2022.300628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel) 2022;14:2569. [PMID: 35626173 DOI: 10.3390/cancers14102569] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Luo QQ, Tian Y, Qu GJ, Kun-Huang, Luo SS. Functional mechanism and clinical implications of miR-141 in human cancers. Cell Signal 2022;:110354. [PMID: 35550172 DOI: 10.1016/j.cellsig.2022.110354] [Reference Citation Analysis]
7 Jahangiri L, Ishola T. Dormancy in Breast Cancer, the Role of Autophagy, lncRNAs, miRNAs and Exosomes. Int J Mol Sci 2022;23:5271. [PMID: 35563661 DOI: 10.3390/ijms23095271] [Reference Citation Analysis]
8 Sawaki M, Shimomura A, Shien T, Iwata H. Management of breast cancer in older patients. Japanese Journal of Clinical Oncology 2022. [DOI: 10.1093/jjco/hyac054] [Reference Citation Analysis]
9 Horimoto Y, Ishizuka Y, Ueki Y, Higuchi T, Arakawa A, Saito M. Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09351-4] [Reference Citation Analysis]
10 Wang Y, Gavan SP, Steinke D, Cheung K, Chen L. Systematic review of the evidence sources applied to cost-effectiveness analyses for older women with primary breast cancer. Cost Eff Resour Alloc 2022;20. [DOI: 10.1186/s12962-022-00342-7] [Reference Citation Analysis]
11 Pawloy K, Urquhart G, Brown D, Daltrey I, Soh F, Anderson LA, Elsberger B. Not all small HER2 positive breast cancers have the same clinical outcome in the North-East of Scotland. Cancer Treatment and Research Communications 2022;31:100549. [DOI: 10.1016/j.ctarc.2022.100549] [Reference Citation Analysis]
12 Connor AE, Kaur M, Sheng JY, Hayes JH. Racial disparities in mortality outcomes among women diagnosed with breast cancer in Maryland: Impact of cardiovascular disease and clinical characteristics. Cancer 2021. [PMID: 34873682 DOI: 10.1002/cncr.33889] [Reference Citation Analysis]
13 Gordon JL, Hinsen KJ, Reynolds MM, Brown MA. Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas. Diseases 2021;9:82. [PMID: 34842655 DOI: 10.3390/diseases9040082] [Reference Citation Analysis]
14 Singh JC, Lichtman SM. Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients. Drugs Aging 2021;38:829-44. [PMID: 34423398 DOI: 10.1007/s40266-021-00889-9] [Reference Citation Analysis]
15 Gupta N, Verma RK, Gupta S, Prinja S. Cost Effectiveness of Trastuzumab for Management of Breast Cancer in India. JCO Glob Oncol 2020;6:205-16. [PMID: 32045547 DOI: 10.1200/JGO.19.00293] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
16 Vazdar L, Gabrić ID, Kruljac I, Pintarić H, Šeparović R, Kirigin Biloš LS, Pavlović M, Tečić Vuger A, Štefanović M. Influence of Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in early-stage HER2 positive breast cancer. Sci Rep 2021;11:14395. [PMID: 34257352 DOI: 10.1038/s41598-021-93634-6] [Reference Citation Analysis]
17 Yan Y, Cheng X, Li L, Zhang R, Zhu Y, Wu Z, Ding K. A Novel Small Molecular Antibody, HER2-Nanobody, Inhibits Tumor Proliferation in HER2-Positive Breast Cancer Cells In Vitro and In Vivo. Front Oncol 2021;11:669393. [PMID: 34055637 DOI: 10.3389/fonc.2021.669393] [Reference Citation Analysis]
18 Yokoyama D, Hisamori S, Deguchi Y, Nishigori T, Okabe H, Kanaya S, Manaka D, Kadokawa Y, Hata H, Minamiguchi S, Tsunoda S, Obama K, Sakai Y. PTEN is a predictive biomarker of trastuzumab resistance and prognostic factor in HER2-overexpressing gastroesophageal adenocarcinoma. Sci Rep 2021;11:9013. [PMID: 33907203 DOI: 10.1038/s41598-021-88331-3] [Reference Citation Analysis]
19 Suzuki T, Kano S, Suzuki M, Yasukawa S, Mizumachi T, Tsushima N, Hatanaka KC, Hatanaka Y, Matsuno Y, Homma A. Enhanced Angiogenesis in Salivary Duct Carcinoma Ex-Pleomorphic Adenoma. Front Oncol 2020;10:603717. [PMID: 33692941 DOI: 10.3389/fonc.2020.603717] [Reference Citation Analysis]
20 Mondaca JM, Guijarro ACC, Flamini MI, Sanchez AM. Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer. Breast Cancer Res Treat 2021;186:363-77. [PMID: 33474679 DOI: 10.1007/s10549-020-06089-0] [Reference Citation Analysis]
21 Sakai K, Chambers JK, Uchida K, Nakagawa T, Nishimura R, Yonezawa T, Maeda S. ErbB2 copy number gain is associated with adverse outcome in canine mammary carcinoma. J Vet Med Sci 2021;83:370-7. [PMID: 33473058 DOI: 10.1292/jvms.20-0483] [Reference Citation Analysis]
22 Sakai K, Shinohara Y, Kaji K, Yonezawa T, Momoi Y, Maeda S. Human epidermal growth factor receptor 2 is overexpressed in canine prostate carcinoma. Translational and Regulatory Sciences 2021;3:1-8. [DOI: 10.33611/trs.2020-018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Cheun JH, Won J, Jung JG, Kim HK, Han W, Lee HB. Impact of Trastuzumab on Ipsilateral Breast Tumor Recurrence for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer after Breast-Conserving Surgery. J Breast Cancer 2021;24:301-14. [PMID: 34190441 DOI: 10.4048/jbc.2021.24.e33] [Reference Citation Analysis]
24 Vermij L, Horeweg N, Leon-Castillo A, Rutten TA, Mileshkin LR, Mackay HJ, Leary A, Powell ME, Singh N, Crosbie EJ, Smit VTHBM, Creutzberg CL, Bosse T. HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. Cancers (Basel) 2020;13:E44. [PMID: 33375706 DOI: 10.3390/cancers13010044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ella-Tongwiis P, Lamb RM, Makanga A, Shergill I, Hughes SF. The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients. BMC Urol 2020;20:187. [PMID: 33238953 DOI: 10.1186/s12894-020-00759-3] [Reference Citation Analysis]
26 Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, Addison D, Baliga R, Stover DG, VanDeusen J, Williams N, Cherian M, Lustberg M, Wesolowski R, Ramaswamy B. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardiooncology 2020;6:26. [PMID: 33292843 DOI: 10.1186/s40959-020-00081-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Dackus GMHE, Jóźwiak K, van der Wall E, van Diest PJ, Hauptmann M, Siesling S, Sonke GS, Linn SC. Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer. Breast Cancer Res Treat 2021;185:817-30. [PMID: 33113088 DOI: 10.1007/s10549-020-05978-8] [Reference Citation Analysis]
28 Stewart P, Blanchette P, Shah PS, Ye XY, Boldt RG, Fernandes R, Vandenberg T, Raphael J. Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis. Breast 2020;54:203-10. [PMID: 33130486 DOI: 10.1016/j.breast.2020.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Kaumaya PTP, Guo L, Overholser J, Penichet ML, Bekaii-Saab T. Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model. Oncoimmunology 2020;9:1818437. [PMID: 33117602 DOI: 10.1080/2162402X.2020.1818437] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
30 Chiang ZC, Chiu YK, Lee CC, Hsu NS, Tsou YL, Chen HS, Hsu HR, Yang TJ, Yang AS, Wang AH. Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells. PLoS One 2020;15:e0239813. [PMID: 32986768 DOI: 10.1371/journal.pone.0239813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Blancas I, Martín-Pérez FJ, Garrido JM, Rodríguez-Serrano F. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast 2020;54:106-13. [PMID: 32977298 DOI: 10.1016/j.breast.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technol Assess 2020;24:1-190. [PMID: 32880572 DOI: 10.3310/hta24400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Ly L, Cheng X, Murthy SRK, Zhuang T, Jones OZ, Basadonna G, Keidar M, Canady J. Canady cold plasma conversion system treatment: An effective inhibitor of cell viability in breast cancer molecular subtypes. Clinical Plasma Medicine 2020;19-20:100109. [DOI: 10.1016/j.cpme.2020.100109] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Chang JH, Cheng CC, Lu YY, Chen YC, Chen SA, Chen YJ. Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling. Iran J Basic Med Sci 2020;23:865-70. [PMID: 32774807 DOI: 10.22038/ijbms.2020.44651.10432] [Reference Citation Analysis]
35 Tang W, Mu D, Han L, Guo X, Han B, Song D. Screening of Clinical Factors Related to Prognosis of Breast Cancer Based on the Cox Proportional Risk Model. J Comput Biol 2021;28:89-98. [PMID: 32757947 DOI: 10.1089/cmb.2019.0110] [Reference Citation Analysis]
36 Doroshow DB, Doroshow JH. From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. Cancer J 2019;25:245-53. [PMID: 31335388 DOI: 10.1097/PPO.0000000000000386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Sung SY, Lee JH, Yang KH, Seo Y, Kang MY. Coronary Event Analysis in Breast Cancer Patients Who Received Breast-Conserving Surgery and Post-Operative Radiotherapy: a Korean Nationwide Cohort Study. J Breast Cancer 2020;23:291-302. [PMID: 32595991 DOI: 10.4048/jbc.2020.23.e30] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Rausch M, Weiss A, Achkhanian J, Rotari A, Nowak-Sliwinska P. Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma. Br J Cancer 2020;123:556-67. [PMID: 32439932 DOI: 10.1038/s41416-020-0890-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
39 Rinaldi J, Sokol ES, Hartmaier RJ, Trabucco SE, Frampton GM, Goldberg ME, Albacker LA, Daemen A, Manning G. The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. PLoS One 2020;15:e0231999. [PMID: 32374727 DOI: 10.1371/journal.pone.0231999] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
40 Tafreshi NK, Morse DL, Lee MC. Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. World J Clin Oncol 2020; 11(4): 169-179 [PMID: 32355639 DOI: 10.5306/wjco.v11.i4.169] [Reference Citation Analysis]
41 Alshaker H, Thrower H, Pchejetski D. Sphingosine Kinase 1 in Breast Cancer-A New Molecular Marker and a Therapy Target. Front Oncol 2020;10:289. [PMID: 32266132 DOI: 10.3389/fonc.2020.00289] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
42 Agabeigi R, Rasta SH, Rahmati-Yamchi M, Salehi R, Alizadeh E. Novel Chemo-Photothermal Therapy in Breast Cancer Using Methotrexate-Loaded Folic Acid Conjugated Au@SiO2 Nanoparticles. Nanoscale Res Lett 2020;15:62. [PMID: 32189075 DOI: 10.1186/s11671-020-3295-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
43 Tran P, Banerjee P. Iatrogenic Decompensated Heart Failure. Curr Heart Fail Rep 2020;17:21-7. [PMID: 32086714 DOI: 10.1007/s11897-020-00452-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Wang J, Luo J, Jin K, Wang X, Yang Z, Ma J, Mei X, Wang X, Zhou Z, Yu X, Chen X, Guo X. Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients. Cancer Med 2020;9:2427-34. [PMID: 32048817 DOI: 10.1002/cam4.2904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Zhang C, Han M, Zhang F, Yang X, Du J, Zhang H, Li W, Chen S. Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle. Int J Nanomedicine 2020;15:885-900. [PMID: 32103944 DOI: 10.2147/IJN.S231144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Guo J, Li Q, Zhang P, Yuan P, Wang J, Ma F, Fan Y, Cai R, Luo Y, Li Q, Xu B. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients. Chin J Cancer Res 2019;31:759-70. [PMID: 31814680 DOI: 10.21147/j.issn.1000-9604.2019.05.06] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
47 Wang B, Ding W, Sun K, Wang X, Xu L, Teng X. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results. Sci Rep 2019;9:16726. [PMID: 31723206 DOI: 10.1038/s41598-019-53003-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
48 Nowsheen S, Aziz K, Park JY, Lerman A, Villarraga HR, Ruddy KJ, Herrmann J. Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction. J Am Heart Assoc 2018;7:e008637. [PMID: 30371238 DOI: 10.1161/JAHA.118.008637] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 6.3] [Reference Citation Analysis]
49 Tang M, Schaffer A, Kiely BE, Daniels B, Simes RJ, Lee CK, Pearson SA. Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007-2016). Br J Cancer 2019;121:904-11. [PMID: 31673103 DOI: 10.1038/s41416-019-0612-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
50 Doroshow DB, Doroshow JH. Genomics and the History of Precision Oncology. Surg Oncol Clin N Am 2020;29:35-49. [PMID: 31757312 DOI: 10.1016/j.soc.2019.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
51 Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, Hong DS, Rodon J, Shaw KM, Piha-Paul SA, Meric-Bernstam F. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol 2019;3:PO. [PMID: 32923865 DOI: 10.1200/PO.18.00345] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ, Chen K, Lazar AJ, Fields RC, Wendl MC, Van Tine BA, Vij R, Chen F, Nykter M, Shmulevich I, Ding L; Fusion Analysis Working Group., Cancer Genome Atlas Research Network. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep 2018;23:227-238.e3. [PMID: 29617662 DOI: 10.1016/j.celrep.2018.03.050] [Cited by in Crossref: 192] [Cited by in F6Publishing: 172] [Article Influence: 64.0] [Reference Citation Analysis]
53 Halilovic A, Verweij DI, Simons A, Stevens-Kroef MJPL, Vermeulen S, Elsink J, Tops BBJ, Otte-Höller I, van der Laak JAWM, van de Water C, Boelens OBA, Schlooz-Vries MS, Dijkstra JR, Nagtegaal ID, Tol J, van Cleef PHJ, Span PN, Bult P. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study. Sci Rep 2019;9:11679. [PMID: 31406196 DOI: 10.1038/s41598-019-48212-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
54 Dong B, Yang Y, Han A, Zhang S, Lin Z, Wang Y, Piao J. Ectopic expression of HSDL2 is related to cell proliferation and prognosis in breast cancer. Cancer Manag Res 2019;11:6531-42. [PMID: 31372054 DOI: 10.2147/CMAR.S205316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Genuino AJ, Chaikledkaew U, The DO, Reungwetwattana T, Thakkinstian A. Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2019;12:815-24. [PMID: 31287333 DOI: 10.1080/17512433.2019.1637252] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
56 Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393:2599-2612. [PMID: 31178152 DOI: 10.1016/s0140-6736(19)30650-6] [Cited by in Crossref: 91] [Cited by in F6Publishing: 51] [Article Influence: 30.3] [Reference Citation Analysis]
57 Ansaripour A, Uyl-de Groot CA, Redekop WK. Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy. Pharmacoeconomics 2018;36:91-103. [PMID: 28795341 DOI: 10.1007/s40273-017-0557-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
58 Koga Y, Ochiai A. Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. Cells 2019;8:E418. [PMID: 31064068 DOI: 10.3390/cells8050418] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
59 Fararjeh AS, Chen LC, Ho YS, Cheng TC, Liu YR, Chang HL, Chang HW, Wu CH, Tu SH. Proteasome 26S Subunit, non-ATPase 3 (PSMD3) Regulates Breast Cancer by Stabilizing HER2 from Degradation. Cancers (Basel) 2019;11:E527. [PMID: 31013812 DOI: 10.3390/cancers11040527] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
60 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Reference Citation Analysis]
62 Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019;4:e000444. [PMID: 30962959 DOI: 10.1136/esmoopen-2018-000444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Chen X, Mangala LS, Rodriguez-Aguayo C, Kong X, Lopez-Berestein G, Sood AK. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev 2018;37:107-24. [PMID: 29243000 DOI: 10.1007/s10555-017-9717-6] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 29.3] [Reference Citation Analysis]
64 Ohtani K, Ide T, Hiasa KI, Sakamoto I, Yamashita N, Kubo M, Tsutsui H. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol 2019;108:1128-39. [PMID: 30859381 DOI: 10.1007/s00392-019-01448-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
65 Huang M, Hunter T, Slomovitz B, Schlumbrecht M. Impact of molecular testing in clinical practice in gynecologic cancers. Cancer Med 2019;8:2013-9. [PMID: 30848097 DOI: 10.1002/cam4.2064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
66 Gershon N, Berchenko Y, Hall PS, Goldstein DA. Cost effectiveness and affordability of trastuzumab in sub-Saharan Africa for early stage HER2-positive breast cancer. Cost Eff Resour Alloc 2019;17:5. [PMID: 30867655 DOI: 10.1186/s12962-019-0174-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
67 Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP. Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors. Clin Cancer Res 2019;25:3495-507. [PMID: 30804020 DOI: 10.1158/1078-0432.CCR-18-3997] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
68 Yoon HJ, Kim KH, Kim HY, Park H, Cho JY, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC. Impacts of non-recovery of trastuzumab-induced cardiomyopathy on clinical outcomes in patients with breast cancer. Clin Res Cardiol 2019;108:892-900. [PMID: 30737527 DOI: 10.1007/s00392-019-01417-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
69 Henry S, Bond R, Rosen S, Grines C, Mieres J. Challenges in Cardiovascular Risk Prediction and Stratification in Women. Cardiovascular Innovations and Applications 2019;3:329-48. [DOI: 10.15212/cvia.2017.0068] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Shibata T, Tokunaga E, Hattori S, Watari K, Murakami Y, Yamashita N, Oki E, Itou J, Toi M, Maehara Y, Kuwano M, Ono M. Y-box binding protein YBX1 and its correlated genes as biomarkers for poor outcomes in patients with breast cancer. Oncotarget 2018;9:37216-28. [PMID: 30647855 DOI: 10.18632/oncotarget.26469] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
71 Lidbrink E, Chmielowska E, Otremba B, Bouhlel A, Lauer S, Liste Hermoso M, Nüesch E, Shing M, Misra V. A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Res Treat 2019;174:187-96. [PMID: 30506110 DOI: 10.1007/s10549-018-5058-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
72 You SH, Chae BJ, Eom YH, Yoo TK, Kim YS, Kim JS, Park WC. Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data. J Breast Cancer 2018;21:415-24. [PMID: 30607163 DOI: 10.4048/jbc.2018.21.e53] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
73 Wilson FR, Coombes ME, Brezden-Masley C, Yurchenko M, Wylie Q, Douma R, Varu A, Hutton B, Skidmore B, Cameron C. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. Syst Rev 2018;7:191. [PMID: 30428932 DOI: 10.1186/s13643-018-0854-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
74 Ansaripour A, Zendehdel K, Tadayon N, Sadeghi F, Uyl-de Groot CA, Redekop WK. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran. PLoS One 2018;13:e0205079. [PMID: 30273393 DOI: 10.1371/journal.pone.0205079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
75 Kurozumi S, Yamaguchi Y, Matsumoto H, Inoue K, Kurosumi M, Oyama T, Horiguchi J, Fujii T, Shirabe K. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer. Med Mol Morphol 2019;52:90-8. [PMID: 30259117 DOI: 10.1007/s00795-018-0206-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
76 Kosaka Y, Minatani N, Tanaka Y, Shida A, Kikuchi M, Nishimiya H, Waraya M, Katoh H, Sato T, Sengoku N, Tanino H, Yamashita K, Watanabe M. Lymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer. Mol Clin Oncol 2018;9:566-74. [PMID: 30402236 DOI: 10.3892/mco.2018.1716] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
77 Shah AN, Gradishar WJ. Adjuvant Anthracyclines in Breast Cancer: What Is Their Role? Oncologist 2018;23:1153-61. [PMID: 30120159 DOI: 10.1634/theoncologist.2017-0672] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
78 Wu Y, Meng Q, Yang Z, Shi L, Hu R, Zhang P, Wei J, Ren J, Leng B, Xu D, Jiang GQ. Circulating HER-2 mRNA in the peripheral blood as a potential diagnostic and prognostic biomarker in females with breast cancer. Oncol Lett 2018;16:3726-34. [PMID: 30127983 DOI: 10.3892/ol.2018.9091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Kittaka N, Tokui R, Ota C, Hashimoto Y, Motomura K, Ishitobi M, Nakayama T, Tamaki Y. A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery. Int J Clin Oncol 2018;23:860-6. [PMID: 29789974 DOI: 10.1007/s10147-018-1297-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
80 Yersal Ö, Eryilmaz U, Akdam H, Meydan N, Barutca S. Arterial Stiffness in Breast Cancer Patients Treated with Anthracycline and Trastuzumab-Based Regimens. Cardiol Res Pract 2018;2018:5352914. [PMID: 29854434 DOI: 10.1155/2018/5352914] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
81 Yu J, Qin B, Moyer AM, Nowsheen S, Liu T, Qin S, Zhuang Y, Liu D, Lu SW, Kalari KR, Visscher DW, Copland JA, McLaughlin SA, Moreno-Aspitia A, Northfelt DW, Gray RJ, Lou Z, Suman VJ, Weinshilboum R, Boughey JC, Goetz MP, Wang L. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 2018;128:2376-88. [PMID: 29708513 DOI: 10.1172/JCI97924] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 13.5] [Reference Citation Analysis]
82 Patsou ED, Karamouzis MV. Response: Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials. ESMO Open 2018;3:e000333. [PMID: 29683152 DOI: 10.1136/esmoopen-2018-000333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Qi L, Zhang B, Zhang S, Ci X, Wu Q, Ma G, Luo A, Fu L, King JL, Nahta R, Dong JT. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression. Oncotarget 2017;8:36054-66. [PMID: 28415602 DOI: 10.18632/oncotarget.16425] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
84 Emeriau N, de Clippele M, Gailly P, Tajeddine N. Store operated calcium entry is altered by the inhibition of receptors tyrosine kinase. Oncotarget 2018;9:16059-73. [PMID: 29662626 DOI: 10.18632/oncotarget.24685] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
85 Erickson KE, Rukhlenko OS, Posner RG, Hlavacek WS, Kholodenko BN. New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. Semin Cancer Biol 2019;54:162-73. [PMID: 29518522 DOI: 10.1016/j.semcancer.2018.02.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
86 Yu T, Cho BJ, Choi EJ, Park JM, Kim DH, Kim IA. Radiosensitizing effect of lapatinib in human epidermal growth factor receptor 2-positive breast cancer cells. Oncotarget 2016;7:79089-100. [PMID: 27738326 DOI: 10.18632/oncotarget.12597] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
87 Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, Dent S, Kondapalli L, Ky B, Okwuosa T, Piña IL, Volgman AS; American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation 2018;137:e30-66. [PMID: 29437116 DOI: 10.1161/CIR.0000000000000556] [Cited by in Crossref: 223] [Cited by in F6Publishing: 117] [Article Influence: 55.8] [Reference Citation Analysis]
88 Pareja F, Marchiò C, Reis-filho JS. Molecular diagnosis in breast cancer. Diagnostic Histopathology 2018;24:71-82. [DOI: 10.1016/j.mpdhp.2018.01.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
89 Motoshima S, Yonemoto K, Kamei H, Morita M, Yamaguchi R. Prognostic implications of HER2 heterogeneity in gastric cancer. Oncotarget. 2018;9:9262-9272. [PMID: 29507688 DOI: 10.18632/oncotarget.24265] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
90 Miolo G, Muraro E, Caruso D, Crivellari D, Ash A, Scalone S, Lombardi D, Rizzolio F, Giordano A, Corona G. Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget 2016;7:39809-22. [PMID: 27223427 DOI: 10.18632/oncotarget.9489] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 11.3] [Reference Citation Analysis]
91 Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, Gazawi N, Rezek D, Wischnik A, Hielscher C, Schleif N, Cirrincione U, Hinke A, Feisel-Schwickardi G. Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study. BMC Cancer 2018;18:51. [PMID: 29310623 DOI: 10.1186/s12885-017-3857-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
92 Bastos DCA, Maldaun MVC, Sawaya R, Suki D, Lang FF, Brown PD, Rao G, Weinberg JS, Prabhu SS. Biological subtypes and survival outcomes in breast cancer patients with brain metastases in the targeted therapy era. Neurooncol Pract 2018;5:161-9. [PMID: 31386016 DOI: 10.1093/nop/npx033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
93 Davari M, Amani B, Mokarian F, Hoseini M, Akbarzadeh A, Heidarzadeh Khoramabadi N. Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis. Med J Islam Repub Iran 2017;31:88. [PMID: 29951389 DOI: 10.14196/mjiri.31.88] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
94 Patsou ED, Alexias GD, Anagnostopoulos FG, Karamouzis MV. Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials. ESMO Open 2017;2:e000271. [PMID: 29259819 DOI: 10.1136/esmoopen-2017-000271] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
95 Budczies J, Pfarr N, Stenzinger A, Treue D, Endris V, Ismaeel F, Bangemann N, Blohmer JU, Dietel M, Loibl S. Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment. Oncotarget. 2016;7:13236-13247. [PMID: 26910888 DOI: 10.18632/oncotarget.7451] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
96 Chan CWH, Law BMH, So WKW, Chow KM, Waye MMY. Novel Strategies on Personalized Medicine for Breast Cancer Treatment: An Update. Int J Mol Sci 2017;18:E2423. [PMID: 29140300 DOI: 10.3390/ijms18112423] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
97 Cho JH, Lim JY, Cho JY. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer. World J Gastroenterol 2017; 23(41): 7407-7414 [PMID: 29151694 DOI: 10.3748/wjg.v23.i41.7407] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
98 Yoshida A, Hayashi N. Reply to Kadri Altundag. J Surg Oncol 2018;117:329. [PMID: 28968921 DOI: 10.1002/jso.24838] [Reference Citation Analysis]
99 Baldassarre T, Truesdell P, Craig AW. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. Breast Cancer Res 2017;19:110. [PMID: 28974266 DOI: 10.1186/s13058-017-0900-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
100 Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res 2017;50:33. [PMID: 28969709 DOI: 10.1186/s40659-017-0140-9] [Cited by in Crossref: 216] [Cited by in F6Publishing: 211] [Article Influence: 43.2] [Reference Citation Analysis]
101 Florido R, Smith KL, Cuomo KK, Russell SD. Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc 2017;6:e006915. [PMID: 28939718 DOI: 10.1161/JAHA.117.006915] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
102 Han X, Zhou Y, Liu W. Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy. NPJ Precis Oncol 2017;1:31. [PMID: 29872712 DOI: 10.1038/s41698-017-0034-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
103 Hao S, Tian W, Gao B, Jiang Y, Zhang X, Zhang S, Guo L, Zhao J, Zhang G, Hu C, Yan J, Luo D. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials. Oncotarget 2017;8:19923-33. [PMID: 28199966 DOI: 10.18632/oncotarget.15252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
104 Li J, Wang S, Wang Y, Wang X, Wang H, Feng J, Zhang Q, Sun T, Ouyang Q, Yin Y, Liu Y, Geng C, Yan M, Jiang Z. Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China. Oncologist 2017;22:1333-8. [PMID: 28798274 DOI: 10.1634/theoncologist.2017-0088] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
105 Gegechkori N, Haines L, Lin JJ. Long-Term and Latent Side Effects of Specific Cancer Types. Med Clin North Am 2017;101:1053-73. [PMID: 28992854 DOI: 10.1016/j.mcna.2017.06.003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 9.6] [Reference Citation Analysis]
106 Lee JS, Kim SH, Im SA, Kim MA, Han JK. Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics. Korean J Radiol. 2017;18:809-820. [PMID: 28860898 DOI: 10.3348/kjr.2017.18.5.809] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
107 Ma CX, Bose R, Gao F, Freedman RA, Telli ML, Kimmick G, Winer E, Naughton M, Goetz MP, Russell C, Tripathy D, Cobleigh M, Forero A, Pluard TJ, Anders C, Niravath PA, Thomas S, Anderson J, Bumb C, Banks KC, Lanman RB, Bryce R, Lalani AS, Pfeifer J, Hayes DF, Pegram M, Blackwell K, Bedard PL, Al-Kateb H, Ellis MJC. Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer. Clin Cancer Res 2017;23:5687-95. [PMID: 28679771 DOI: 10.1158/1078-0432.CCR-17-0900] [Cited by in Crossref: 101] [Cited by in F6Publishing: 56] [Article Influence: 20.2] [Reference Citation Analysis]
108 Jacquinot Q, Meneveau N, Chatot M, Bonnetain F, Degano B, Bouhaddi M, Dumoulin G, Vernerey D, Pivot X, Mougin F. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study. BMC Cancer 2017;17:425. [PMID: 28629338 DOI: 10.1186/s12885-017-3420-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
109 Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Morrow M, Hunt KK. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial. Ann Surg. 2016;264:413-420. [PMID: 27513155 DOI: 10.1097/sla.0000000000001863] [Cited by in Crossref: 243] [Cited by in F6Publishing: 89] [Article Influence: 48.6] [Reference Citation Analysis]
110 Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol. 2017;34:119. [PMID: 28526922 DOI: 10.1007/s12032-017-0975-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
111 Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 2017;23:5123-34. [PMID: 28487443 DOI: 10.1158/1078-0432.CCR-16-2191] [Cited by in Crossref: 55] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
112 Yavas G, Celik E, Yavas C, Elsurer C, Afsar RE. Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy. Rep Pract Oncol Radiother 2017;22:295-302. [PMID: 28507459 DOI: 10.1016/j.rpor.2017.01.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
113 Wong CY, Jiang H, Abel PW, Scofield MA, Xie Y, Wei T, Tu Y. Phorbol myristate acetate suppresses breast cancer cell growth via down-regulation of P-Rex1 expression. Protein Cell 2016;7:445-9. [PMID: 27020455 DOI: 10.1007/s13238-016-0261-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
114 Seferina SC, Ramaekers BLT, de Boer M, Dercksen MW, van den Berkmortel F, van Kampen RJW, van de Wouw AJ, Voogd AC, Tjan Heijnen VCG, Joore MA. Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium. Oncotarget 2017;8:79223-33. [PMID: 29108301 DOI: 10.18632/oncotarget.16985] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
115 McGuire A, Kalinina O, Holian E, Curran C, Malone CA, McLaughlin R, Lowery A, Brown JAL, Kerin MJ. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab. Breast Cancer Res Treat 2017;164:221-9. [PMID: 28378298 DOI: 10.1007/s10549-017-4225-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
116 Clarke CS, Hunter RM, Shemilt I, Serra-Sastre V. Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective. PLoS One 2017;12:e0172731. [PMID: 28248984 DOI: 10.1371/journal.pone.0172731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
117 Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389:1195-1205. [PMID: 28215665 DOI: 10.1016/s0140-6736(16)32616-2] [Cited by in Crossref: 370] [Cited by in F6Publishing: 197] [Article Influence: 74.0] [Reference Citation Analysis]
118 Inwald EC, Ortmann O, Koller M, Zeman F, Hofstädter F, Evert M, Brockhoff G, Klinkhammer-Schalke M. Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology. Breast Cancer Res Treat 2017;163:119-30. [PMID: 28205042 DOI: 10.1007/s10549-017-4151-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
119 Cao L, Cai G, Xu F, Yang ZZ, Yu XL, Ma JL, Zhang Q, Wu J, Guo XM, Chen JY. Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy. Medicine (Baltimore) 2016;95:e4230. [PMID: 27512838 DOI: 10.1097/MD.0000000000004230] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
120 Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, Gazawi N, Rezek D, Wischnik A, Hielscher C, Keitel S, Cirrincione U, Hinke A, Feisel-Schwickardi G. Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Results of a Prospective, Noninterventional Study on Routine Treatment Between 2006 and 2012 in Germany. Oncologist 2017;22:131-8. [PMID: 28174294 DOI: 10.1634/theoncologist.2016-0193] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
121 Buzatto IP, Ribeiro-Silva A, Andrade JM, Carrara HH, Silveira WA, Tiezzi DG. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors. Braz J Med Biol Res 2017;50:e5674. [PMID: 28146217 DOI: 10.1590/1414-431X20165674] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
122 Hamed RH, Salim K, Alzahrani A, Elsamany S. Cardiotoxicity of the adjuvant trastuzumab in a Saudi population: clinical experience of a single institution. Forum of Clinical Oncology 2016;7:1-6. [DOI: 10.1515/fco-2016-0007] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
123 Yoon HJ, Kim KH, Kim JY, Park HJ, Cho JY, Hong YJ, Park HW, Kim JH, Ahn Y, Jeong MH, Cho JG, Park JC. Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer. J Breast Cancer 2016;19:402-9. [PMID: 28053628 DOI: 10.4048/jbc.2016.19.4.402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
124 Prendergast EN, Elvin JA. Genomic profiling of gynecologic cancers and implications for clinical practice. Curr Opin Obstet Gynecol 2017;29:18-25. [PMID: 27984344 DOI: 10.1097/GCO.0000000000000335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
125 Iborra S, Stickeler E. HER2-Orientated Therapy in Early and Metastatic Breast Cancer. Breast Care (Basel) 2016;11:392-7. [PMID: 28228705 DOI: 10.1159/000453603] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
126 Davidson M, Starling N. Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. Onco Targets Ther. 2016;9:7235-7245. [PMID: 27932891 DOI: 10.2147/ott.s100643] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
127 Cao L, Cai G, Chang C, Yang ZZ, Feng Y, Yu XL, Ma JL, Wu J, Guo XM, Chen JY. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab. Oncotarget 2016;7:1042-54. [PMID: 26460956 DOI: 10.18632/oncotarget.6053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
128 Keshavan MS, Lawler AN, Nasrallah HA, Tandon R. New drug developments in psychosis: Challenges, opportunities and strategies. Prog Neurobiol 2017;152:3-20. [PMID: 27519538 DOI: 10.1016/j.pneurobio.2016.07.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
129 Leone J, Leone BA, Leone JP. Adjuvant systemic therapy in older women with breast cancer. Breast Cancer (Dove Med Press) 2016;8:141-7. [PMID: 27524919 DOI: 10.2147/BCTT.S110765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
130 Sabnis AJ, Guerriero CJ, Olivas V, Sayana A, Shue J, Flanagan J, Asthana S, Paton AW, Paton JC, Gestwicki JE, Walter P, Weissman JS, Wipf P, Brodsky JL, Bivona TG. Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proc Natl Acad Sci U S A 2016;113:9015-20. [PMID: 27450084 DOI: 10.1073/pnas.1603883113] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
131 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
132 Henri C, Heinonen T, Tardif JC. The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy. Biomark Cancer 2016;8:39-45. [PMID: 27257396 DOI: 10.4137/BIC.S31798] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
133 Kristeleit H, Parton M, Beresford M, Macpherson IR, Sharma R, Lazarus L, Kelleher M. Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. Target Oncol 2016;11:579-91. [PMID: 27181019 DOI: 10.1007/s11523-016-0438-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
134 Matsusaka K, Ishikawa S, Nakayama A, Ushiku T, Nishimoto A, Urabe M, Kaneko N, Kunita A, Kaneda A, Aburatani H, Fujishiro M, Seto Y, Fukayama M. Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens. PLoS One 2016;11:e0154430. [PMID: 27119558 DOI: 10.1371/journal.pone.0154430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
135 Huszno J, Nowara E. Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients. Contemp Oncol (Pozn) 2016;20:1-7. [PMID: 27095932 DOI: 10.5114/wo.2016.58495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
136 Wu YY, Huang TC, Tsai TN, Chen JH, Dai MS, Chang PY, Ho CL, Ye RH, Chung TR, Chen YC, Chao TY. The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis. PLoS One 2016;11:e0151112. [PMID: 26953588 DOI: 10.1371/journal.pone.0151112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
137 Chin-Yee NJ, Yan AT, Kumachev A, Ko D, Earle C, Tomlinson G, Trudeau ME, Krahn M, Krzyzanowska M, Pal R, Brezden-Masley C, Gavura S, Lien K, Chan K. Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study. CMAJ Open 2016;4:E66-72. [PMID: 27280116 DOI: 10.9778/cmajo.20150033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
138 Casey MC, Sweeney KJ, Brown JA, Kerin MJ. Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer 2016;139:12-22. [PMID: 26756433 DOI: 10.1002/ijc.29985] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
139 Dvortsin E, Gout-Zwart J, Eijssen EL, van Brussel J, Postma MJ. Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer. PLoS One 2016;11:e0146551. [PMID: 26800029 DOI: 10.1371/journal.pone.0146551] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
140 Shoji K, Yoneda M, Fujiyuki T, Amagai Y, Tanaka A, Matsuda A, Ogihara K, Naya Y, Ikeda F, Matsuda H, Sato H, Kai C. Development of new therapy for canine mammary cancer with recombinant measles virus. Mol Ther Oncolytics 2016;3:15022. [PMID: 27119113 DOI: 10.1038/mto.2015.22] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
141 Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD; HREA Study Team. Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. Breast Cancer Res Treat 2016;155:127-32. [PMID: 26708471 DOI: 10.1007/s10549-015-3656-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
142 Calce E, Saviano M, De Luca S. Development of Targeting Ligands for HER2 Receptor: Simplified Receptor Model Employed for Selecting Highly Specific Molecules. Int J Pept Res Ther 2016;22:237-42. [DOI: 10.1007/s10989-015-9503-7] [Reference Citation Analysis]
143 Dittmar Y, Settmacher U. Individualized treatment of gastric cancer: Impact of molecular biology and pathohistological features. World J Gastrointest Oncol 2015; 7(11): 292-302 [PMID: 26600929 DOI: 10.4251/wjgo.v7.i11.292] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
144 Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL. Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J Immunother Cancer 2015;3:41. [PMID: 26380087 DOI: 10.1186/s40425-015-0084-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
145 Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Mol Oncol 2016;10:138-47. [PMID: 26422389 DOI: 10.1016/j.molonc.2015.09.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
146 Braga VM, de Oliveira MB, Netto CC, Ibrahim RE, Peixoto RD. Human Epidermal Growth Factor Receptor 2-Positive Duodenal Adenocarcinoma: A Case Report and Review of the Literature. Case Rep Oncol 2015;8:285-9. [PMID: 26351435 DOI: 10.1159/000437257] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
147 Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, Takeyoshi I, Oyama T. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer 2015;15:622. [PMID: 26345461 DOI: 10.1186/s12885-015-1641-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
148 Akinyemiju T, Moore JX, Altekruse SF. Breast cancer survival in African-American women by hormone receptor subtypes. Breast Cancer Res Treat 2015;153:211-8. [PMID: 26250393 DOI: 10.1007/s10549-015-3528-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
149 Visser A, van de Ven EM, Ruczynski LI, Blaisse RJ, van Halteren HK, Aben K, van Laarhoven HW. Cardiac monitoring during adjuvant trastuzumab therapy: Guideline adherence in clinical practice. Acta Oncol 2016;55:423-9. [PMID: 26217988 DOI: 10.3109/0284186X.2015.1068444] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
150 Gündüz S, Göksu SS, Arslan D, Tatli AM, Uysal M, Gündüz UR, Sevinç MM, Coşkun HS, Bozcuk H, Mutlu H, Savas B. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. Mol Clin Oncol 2015;3:1109-12. [PMID: 26623060 DOI: 10.3892/mco.2015.610] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
151 Harada S, Yanagisawa M, Kaneko S, Yorozu K, Yamamoto K, Moriya Y, Harada N. Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Mol Clin Oncol 2015;3:987-94. [PMID: 26623038 DOI: 10.3892/mco.2015.609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
152 Simmons C, Dent S, Brezden-Masley C. Duration of Trastuzumab. In matters of the heart, one size may not fit all? Eur J Cancer 2015;51:1657-9. [PMID: 26185034 DOI: 10.1016/j.ejca.2015.06.004] [Reference Citation Analysis]
153 Mislang AR, Biganzoli L. Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care? Cancers (Basel) 2015;7:1191-214. [PMID: 26151681 DOI: 10.3390/cancers7030833] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
154 Johnson A, Zeng J, Bailey AM, Holla V, Litzenburger B, Lara-Guerra H, Mills GB, Mendelsohn J, Shaw KR, Meric-Bernstam F. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today 2015;20:1433-8. [PMID: 26148707 DOI: 10.1016/j.drudis.2015.05.013] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 6.4] [Reference Citation Analysis]
155 Seferina SC, Lobbezoo DJ, de Boer M, Dercksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, de Vries B, Joore MA, Peer PG, Voogd AC, Tjan-Heijnen VC. Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium. Oncologist 2015;20:856-63. [PMID: 26099745 DOI: 10.1634/theoncologist.2015-0006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
156 Bethune GC, Veldhuijzen van Zanten D, Macintosh RF, Rayson D, Younis T, Thompson K, Barnes PJ. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for HE. Histopathology 2015;67:880-7. [DOI: 10.1111/his.12723] [Cited by in Crossref: 48] [Article Influence: 6.9] [Reference Citation Analysis]
157 Ligeti B, Pénzváltó Z, Vera R, Győrffy B, Pongor S. A Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial Results. PLoS One 2015;10:e0129267. [PMID: 26047322 DOI: 10.1371/journal.pone.0129267] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
158 Niccolai E, Taddei A, Prisco D, Amedei A. Gastric cancer and the epoch of immunotherapy approaches. World J Gastroenterol 2015; 21(19): 5778-5793 [PMID: 26019442 DOI: 10.3748/wjg.v21.i19.5778] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 56] [Article Influence: 8.1] [Reference Citation Analysis]
159 D'Souza JW, Robinson MK. Oligoclonal antibodies to target the ErbB family. Expert Opin Biol Ther 2015;15:1015-21. [PMID: 25936923 DOI: 10.1517/14712598.2015.1042362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
160 Kinugasa H, Nouso K, Tanaka T, Miyahara K, Morimoto Y, Dohi C, Matsubara T, Okada H, Yamamoto K. Droplet digital PCR measurement of HER2 in patients with gastric cancer. Br J Cancer 2015;112:1652-5. [PMID: 25897674 DOI: 10.1038/bjc.2015.129] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
161 Nuciforo P, Radosevic-Robin N, Ng T, Scaltriti M. Quantification of HER family receptors in breast cancer. Breast Cancer Res. 2015;17:53. [PMID: 25887735 DOI: 10.1186/s13058-015-0561-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
162 Mates M, Fletcher GG, Freedman OC, Eisen A, Gandhi S, Trudeau ME, Dent SF. Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 2015;22:S114-22. [PMID: 25848335 DOI: 10.3747/co.22.2322] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
163 Rigon E, Saggia C, Rossi V, Genestroni S, Gaudino E, Campisi P, Veggiani C, Boldorini RL, Alabiso O. FISH in triple-negative breast cancer: a possible strategy for the future? Future Oncol 2015;11:1023-6. [PMID: 25804117 DOI: 10.2217/fon.15.25] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Yang B, Zhou Y, Zhang L, Cui L. Enrichment design with patient population augmentation. Contemp Clin Trials 2015;42:60-7. [PMID: 25746817 DOI: 10.1016/j.cct.2015.02.010] [Cited by in Crossref: 7] [Article Influence: 1.0] [Reference Citation Analysis]
165 Ricciardi GR, Russo A, Franchina T, Ferraro G, Adamo V. Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases. Onco Targets Ther 2015;8:289-94. [PMID: 25678799 DOI: 10.2147/OTT.S74110] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
166 Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Pusztai L, Ellis C, Eidtmann H, Arribas J, Cortes J, de Azambuja E, Piccart M, Baselga J. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 2015;21:569-76. [PMID: 25467182 DOI: 10.1158/1078-0432.CCR-14-1824] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 7.7] [Reference Citation Analysis]
167 Fayanju OM, Stoll CR, Fowler S, Colditz GA, Margenthaler JA. Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis. Ann Surg 2014;260:1000-10. [PMID: 24950272 DOI: 10.1097/SLA.0000000000000769] [Cited by in Crossref: 68] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
168 Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol. 2015;141:1343-1351. [PMID: 25544671 DOI: 10.1007/s00432-014-1900-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
169 Sueta A, Yamamoto Y, Yamamoto-Ibusuki M, Hayashi M, Takeshita T, Yamamoto S, Iwase H. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. PLoS One 2014;9:e116054. [PMID: 25542038 DOI: 10.1371/journal.pone.0116054] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
170 Lee SB, Lee JW, Yu JH, Ko BS, Kim HJ, Son BH, Gong G, Lee HJ, Kim SB, Jung KH, Ahn JH, Lee W, Sung J, Ahn SH. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. BMC Cancer 2014;14:929. [PMID: 25491647 DOI: 10.1186/1471-2407-14-929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
171 Tu J, Yu Y, Liu W, Chen S. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med. 2015;9:17-24. [PMID: 25452770 DOI: 10.3892/etm.2014.2063] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
172 Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48:223-235. [PMID: 25445234 DOI: 10.1016/j.clinbiochem.2014.10.013] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 8.1] [Reference Citation Analysis]
173 Xu N, Redfern CH, Gordon M, Eppler S, Lum BL, Trudeau C. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study. Cancer Chemother Pharmacol 2014;74:1251-60. [PMID: 25344761 DOI: 10.1007/s00280-014-2603-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
174 Leong D, Rai R, Nguyen B, Lee A, Yip D. Advances in adjuvant systemic therapy for non-small-cell lung cancer. World J Clin Oncol 2014; 5(4): 633-645 [PMID: 25302167 DOI: 10.5306/wjco.v5.i4.633] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
175 Subbiah IM, Gonzalez-Angulo AM. Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future. Curr Treat Options Oncol 2014;15:41-54. [PMID: 24323591 DOI: 10.1007/s11864-013-0262-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
176 Down SK, Lucas O, Benson JR, Wishart GC. Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer. Oncol Lett 2014;8:2757-61. [PMID: 25364461 DOI: 10.3892/ol.2014.2589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
177 Pecot CV, Wu SY, Bellister S, Filant J, Rupaimoole R, Hisamatsu T, Bhattacharya R, Maharaj A, Azam S, Rodriguez-Aguayo C, Nagaraja AS, Morelli MP, Gharpure KM, Waugh TA, Gonzalez-Villasana V, Zand B, Dalton HJ, Kopetz S, Lopez-Berestein G, Ellis LM, Sood AK. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther 2014;13:2876-85. [PMID: 25281617 DOI: 10.1158/1535-7163.MCT-14-0074] [Cited by in Crossref: 57] [Cited by in F6Publishing: 27] [Article Influence: 7.1] [Reference Citation Analysis]
178 Cordo Russo RI, Béguelin W, Díaz Flaqué MC, Proietti CJ, Venturutti L, Galigniana N, Tkach M, Guzmán P, Roa JC, O'Brien NA, Charreau EH, Schillaci R, Elizalde PV. Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. Oncogene 2015;34:3413-28. [PMID: 25174405 DOI: 10.1038/onc.2014.272] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
179 Stickeler E, Fehm T. Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years? Breast Care (Basel) 2014;9:161-7. [PMID: 25177257 DOI: 10.1159/000365129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
180 Onitilo AA, Engel JM, Stankowski RV. Cardiovascular toxicity associated with adjuvant trastuzumab therapy: prevalence, patient characteristics, and risk factors. Ther Adv Drug Saf 2014;5:154-66. [PMID: 25083270 DOI: 10.1177/2042098614529603] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 7.1] [Reference Citation Analysis]
181 Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, Karanikiotis C, Bafaloukos D, Kosmidis P, Samantas E, Varthalitis I, Pavlidis N, Pectasides D, Dimopoulos MA. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. BMC Cancer 2014;14:515. [PMID: 25026897 DOI: 10.1186/1471-2407-14-515] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
182 Matsumoto T, Sasako M, Mizusawa J, Hirota S, Ochiai A, Kushima R, Katai H, Tanaka Y, Fukushima N, Nashimoto A, Tsuburaya A; Stomach Cancer Study Group of the Japan Clinical Oncology Group. HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). Gastric Cancer 2015;18:467-75. [PMID: 24993498 DOI: 10.1007/s10120-014-0398-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
183 Chen M, Li Y, Ming Z, Biao A, Zheng LX. Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer. Contemp Oncol (Pozn) 2014;18:95-9. [PMID: 24966791 DOI: 10.5114/wo.2014.41383] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
184 Harbeck N, Beckmann MW, Rody A, Schneeweiss A, Müller V, Fehm T, Marschner N, Gluz O, Schrader I, Heinrich G, Untch M, Jackisch C. HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer. Breast Care (Basel) 2013;8:49-55. [PMID: 24715843 DOI: 10.1159/000346837] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
185 Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, Hershman DL. Non-initiation and early discontinuation of adjuvant trastuzumab in women with localized HER2-positive breast cancer. Breast Cancer 2014;21:780-5. [PMID: 24902664 DOI: 10.1007/s12282-014-0543-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
186 Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014;3:e29030. [PMID: 25083328 DOI: 10.4161/onci.29030] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
187 Thorley PJ, Bould M, Chowdhury FU. Gated cardiac SPECT: can it be used for serial assessment of left ventricular function in oncology patients? Nucl Med Commun 2013;34:1137-40. [PMID: 24157899 DOI: 10.1097/MNM.0000000000000000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Kramar A, Bachelot T, Madrange N, Pierga JY, Kerbrat P, Espié M, Fumoleau P, Pauporté I, Khayat D, Romieu G, Pivot X. Trastuzumab duration effects within patient prognostic subgroups in the PHARE trial. Ann Oncol 2014;25:1563-70. [PMID: 24827132 DOI: 10.1093/annonc/mdu177] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
189 Watanabe N, Otsuka S, Sasaki Y, Shimojima R, Wani Y, Uchino K. Cardiac tolerability of concurrent administration of trastuzumab and anthracycline-based regimen as adjuvant chemotherapy for breast cancer. Breast Care (Basel) 2014;9:46-51. [PMID: 24803887 DOI: 10.1159/000358754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
190 Marinko T, Dolenc J, Bilban-Jakopin C. Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer. Radiol Oncol 2014;48:105-12. [PMID: 24991199 DOI: 10.2478/raon-2013-0040] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
191 Boessen R, Heerspink HJ, De Zeeuw D, Grobbee DE, Groenwold RH, Roes KC. Improving clinical trial efficiency by biomarker-guided patient selection. Trials 2014;15:103. [PMID: 24690215 DOI: 10.1186/1745-6215-15-103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
192 Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys 2014;88:553-64. [PMID: 24521674 DOI: 10.1016/j.ijrobp.2013.11.012] [Cited by in Crossref: 225] [Cited by in F6Publishing: 182] [Article Influence: 28.1] [Reference Citation Analysis]
193 Sanford M. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer. Target Oncol 2014;9:85-94. [PMID: 24664187 DOI: 10.1007/s11523-014-0313-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
194 Xu L, Guo F, Song S, Zhang G, Liu Y, Xie X. Trastuzumab monotherapy for bone marrow metastasis of breast cancer: A case report. Oncol Lett 2014;7:1951-3. [PMID: 24932266 DOI: 10.3892/ol.2014.1999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
195 Inwald EC, Ortmann O, Zeman F, Koller M, Hofstädter F, Gerstenhauer M, Klinkhammer-Schalke M. Guideline concordant therapy prolongs survival in HER2-positive breast cancer patients: results from a large population-based cohort of a cancer registry. Biomed Res Int 2014;2014:137304. [PMID: 24779005 DOI: 10.1155/2014/137304] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
196 Bachmann C, Schmidt S, Staebler A, Schittenhelm J, Wallwiener D, Grischke EM. Risk factors and survival outcome in cerebral metastatic breast cancer. Med Oncol 2014;31:862. [PMID: 24504842 DOI: 10.1007/s12032-014-0862-2] [Reference Citation Analysis]
197 Chung A, Cui X, Audeh W, Giuliano A. Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer 2013;13:223-32. [PMID: 23829888 DOI: 10.1016/j.clbc.2013.04.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
198 Durães C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch 2014;464:367-78. [DOI: 10.1007/s00428-013-1533-y] [Cited by in Crossref: 95] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
199 Lorenzon L, Mercantini P, Ferri M, La Torre M, Sparagna A, Balducci G, Tarantino G, Romiti A, Pilozzi E, Ziparo V. Profiling the prognosis of gastric cancer patients: is it worth correlating the survival with the clinical/pathological and molecular features of gastric cancers? ScientificWorldJournal 2013;2013:196541. [PMID: 24453810 DOI: 10.1155/2013/196541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
200 Dam DH, Culver KS, Odom TW. Grafting aptamers onto gold nanostars increases in vitro efficacy in a wide range of cancer cell types. Mol Pharm 2014;11:580-7. [PMID: 24422969 DOI: 10.1021/mp4005657] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 7.5] [Reference Citation Analysis]
201 Vucicevic D, Carey EJ, Karlin NJ. Trastuzumab-induced hepatotoxicity: a case report. Breast Care (Basel) 2013;8:146-8. [PMID: 24419371 DOI: 10.1159/000346844] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
202 Rom J, Schumacher C, Gluz O, Höfler J, Eidt S, Domschke C, Marmé F, Nitz U, Sohn C, Schneeweiss A. Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers. Breast Care (Basel) 2013;8:208-14. [PMID: 24415972 DOI: 10.1159/000352094] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
203 Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, Bartsch R, Jensen-Jarolim E, Bergmann M. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. J Transl Med 2013;11:307. [PMID: 24330813 DOI: 10.1186/1479-5876-11-307] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 9.9] [Reference Citation Analysis]
204 Zelle SG, Vidaurre T, Abugattas JE, Manrique JE, Sarria G, Jeronimo J, Seinfeld JN, Lauer JA, Sepulveda CR, Venegas D, Baltussen R. Cost-effectiveness analysis of breast cancer control interventions in Peru. PLoS One 2013;8:e82575. [PMID: 24349314 DOI: 10.1371/journal.pone.0082575] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
205 Miles D, Baselga J, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM. Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 2013;142:89-99. [PMID: 24129974 DOI: 10.1007/s10549-013-2710-z] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
206 Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, Mello RA. Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies. World J Gastroenterol 2013; 19(38): 6383-6397 [PMID: 24151357 DOI: 10.3748/wjg.v19.i38.6383] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
207 de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: A step forward. World J Gastroenterol 2013; 19(37): 6165-6169 [PMID: 24115812 DOI: 10.3748/wjg.v19.i37.6165] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.7] [Reference Citation Analysis]
208 Cheng YC, Rondón G, Anderlini P, Khouri IF, Champlin RE, Ueno NT. Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. J Cancer 2013;4:679-85. [PMID: 24155780 DOI: 10.7150/jca.6775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
209 Niepel M, Hafner M, Pace EA, Chung M, Chai DH, Zhou L, Schoeberl B, Sorger PK. Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci Signal 2013;6:ra84. [PMID: 24065145 DOI: 10.1126/scisignal.2004379] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 7.8] [Reference Citation Analysis]
210 Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, Kodera Y, Nakanishi H. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Gastric Cancer. 2014;17:450-462. [PMID: 23948998 DOI: 10.1007/s10120-013-0290-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
211 Bockmayr M, Klauschen F, Györffy B, Denkert C, Budczies J. New network topology approaches reveal differential correlation patterns in breast cancer. BMC Syst Biol 2013;7:78. [PMID: 23945349 DOI: 10.1186/1752-0509-7-78] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
212 Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Ménard S, Tagliabue E. Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study. Breast Cancer Res Treat 2013;141:101-10. [PMID: 23942848 DOI: 10.1007/s10549-013-2658-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
213 Carney WP, Bernhardt D, Jasani B. Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients? Biomark Cancer 2013;5:31-9. [PMID: 24179396 DOI: 10.4137/BIC.S12389] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
214 Okita Y, Narita Y, Suzuki T, Arita H, Yonemori K, Kinoshita T, Fujiwara Y, Tsuda H, Komoike Y, Nakagawa H, Tamaki Y, Tomita Y, Shibui S, Maruno M. Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. Mol Clin Oncol 2013;1:995-1001. [PMID: 24649283 DOI: 10.3892/mco.2013.162] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
215 Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ; Translational Research in Oncology BCIRG 006 Trial Investigators. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist 2013;18:812-8. [PMID: 23814044 DOI: 10.1634/theoncologist.2013-0091] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
216 Yardley DA. Drug resistance and the role of combination chemotherapy in improving patient outcomes. Int J Breast Cancer 2013;2013:137414. [PMID: 23864953 DOI: 10.1155/2013/137414] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
217 Korkaya H, Wicha MS. HER2 and breast cancer stem cells: more than meets the eye. Cancer Res. 2013;73:3489-3493. [PMID: 23740771 DOI: 10.1158/0008-5472.can-13-0260] [Cited by in Crossref: 85] [Cited by in F6Publishing: 55] [Article Influence: 9.4] [Reference Citation Analysis]
218 Han H, Davis ME. Single-antibody, targeted nanoparticle delivery of camptothecin. Mol Pharm. 2013;10:2558-2567. [PMID: 23676007 DOI: 10.1021/mp300702x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 5.1] [Reference Citation Analysis]
219 Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci 2013;14:11402-23. [PMID: 23759990 DOI: 10.3390/ijms140611402] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
220 Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8:76. [PMID: 23656792 DOI: 10.1186/1746-1596-8-76] [Cited by in Crossref: 38] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
221 Huang SM, Chien LY, Tai CJ, Tseng LM, Chen PH, Tai CJ. Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies. Evid Based Complement Alternat Med 2013;2013:392024. [PMID: 23572054 DOI: 10.1155/2013/392024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
222 Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1-12. [PMID: 23563986 DOI: 10.1007/s10120-013-0252-z] [Cited by in Crossref: 158] [Cited by in F6Publishing: 150] [Article Influence: 17.6] [Reference Citation Analysis]
223 Swanson T, Grills IS, Ye H, Entwistle A, Teahan M, Letts N, Yan D, Duquette J, Vicini FA. Six-year experience routinely using moderate deep inspiration breath-hold for the reduction of cardiac dose in left-sided breast irradiation for patients with early-stage or locally advanced breast cancer. Am J Clin Oncol 2013;36:24-30. [PMID: 22270108 DOI: 10.1097/COC.0b013e31823fe481] [Cited by in Crossref: 98] [Cited by in F6Publishing: 40] [Article Influence: 10.9] [Reference Citation Analysis]
224 Aoyama T, Yoshikawa T, Miyagi Y, Kameda Y, Shirai J, Hayashi T, Cho H, Oshima T, Yukawa N, Rino Y, Masuda M, Tsuburaya A. Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. Surg Today 2013;43:1390-7. [PMID: 23512532 DOI: 10.1007/s00595-013-0544-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
225 Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, Quraishi AA, Ignatoski KW, Daignault S, Davis A, Hall CL, Palanisamy N, Heath AN, Tawakkol N, Luther TK, Clouthier SG, Chadwick WA, Day ML, Kleer CG, Thomas DG, Hayes DF, Korkaya H, Wicha MS. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res. 2013;73:1635-1646. [PMID: 23442322 DOI: 10.1158/0008-5472.can-12-3349] [Cited by in Crossref: 170] [Cited by in F6Publishing: 104] [Article Influence: 18.9] [Reference Citation Analysis]
226 Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF. Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer. Clin Med Insights Oncol 2013;7:41-51. [PMID: 23471238 DOI: 10.4137/CMO.S10811] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
227 Tewari M, Kumar A, Mishra RR, Kumar M, Shukla HS. HER2 Expression in Gastric and Gastroesophageal Cancer: Report from a Tertiary Care Hospital in North India. Indian J Surg 2015;77:447-51. [PMID: 26730043 DOI: 10.1007/s12262-013-0871-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
228 Lee RJ, Armstrong AC, Wardley AM. Emerging targeted combinations in the management of breast cancer. Breast Cancer (Dove Med Press) 2013;5:61-72. [PMID: 24648759 DOI: 10.2147/BCTT.S26771] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
229 Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat 2013;137:449-55. [PMID: 23225147 DOI: 10.1007/s10549-012-2366-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
230 Tabatabaei-Panah AS, Jeddi-Tehrani M, Ghods R, Akhondi MM, Mojtabavi N, Mahmoudi AR, Mirzadegan E, Shojaeian S, Zarnani AH. Accurate sensitivity of quantum dots for detection of HER2 expression in breast cancer cells and tissues. J Fluoresc 2013;23:293-302. [PMID: 23212129 DOI: 10.1007/s10895-012-1147-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
231 Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res 2013;19:610-9. [PMID: 23224399 DOI: 10.1158/1078-0432.CCR-12-2024] [Cited by in Crossref: 74] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
232 Al-Momani H, Barnes R, El-Hadi A, Shah R, Lewis WG, Edwards P. Human epidermal growth factor receptor-2 in oesophageal cancers: An observational study. World J Gastroenterol 2012; 18(44): 6447-6451 [PMID: 23197890 DOI: 10.3748/wjg.v18.i44.6447] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
233 Ahn ER, Wang E, Glück S. Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) 2012;6:191-207. [PMID: 23226023 DOI: 10.4137/BCBCR.S9301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
234 Chien AJ, Rugo HS. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013;137:1-12. [PMID: 23143215 DOI: 10.1007/s10549-012-2328-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
235 Kontani K, Kuroda N, Hashimoto S, Murazawa C, Norimura S, Tanaka H, Ohtani M, Fujiwara-Honjo N, Kushida Y, Date M, Haba R, Houchi H, Yamauchi A, Yokomise H. Clinical usefulness of human epidermal growth factor receptor-2 extracellular domain as a biomarker for monitoring cancer status and predicting the therapeutic efficacy in breast cancer. Cancer Biol Ther 2013;14:20-8. [PMID: 23114645 DOI: 10.4161/cbt.22626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
236 Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, Den Boer ML, van den Heuvel-Eibrink MM, O'Hare T, Druker BJ, Loriaux MM. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res 2013;73:285-96. [PMID: 23087056 DOI: 10.1158/0008-5472.CAN-12-1906] [Cited by in Crossref: 109] [Cited by in F6Publishing: 79] [Article Influence: 10.9] [Reference Citation Analysis]
237 Cho SH, Jeon J, Kim SI. Personalized medicine in breast cancer: a systematic review. J Breast Cancer 2012;15:265-72. [PMID: 23091538 DOI: 10.4048/jbc.2012.15.3.265] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
238 Dent S, Hopkins S, Graham N, Johnson C, Law A, Campbell M, Crawley F, Allen K, Turek M. The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study. Cardiol Res Pract 2012;2012:135819. [PMID: 23050193 DOI: 10.1155/2012/135819] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
239 Okines AF, Cunningham D. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer. Therap Adv Gastroenterol. 2012;5:301-318. [PMID: 22973416 DOI: 10.1177/1756283x12450246] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
240 Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, Frey N, Mager DE. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 2012;92:520-7. [PMID: 22968044 DOI: 10.1038/clpt.2012.153] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
241 Wu X, Zhang J, Zhen R, Lv J, Zheng L, Su X, Zhu G, Gavine PR, Xu S, Lu S. Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. J Transl Med. 2012;10:180. [PMID: 22935382 DOI: 10.1186/1479-5876-10-180] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
242 Abramson VG, Mayer IA. Improving survival and limiting toxicity: latest advances in treating human epidermal growth factor receptor 2 overexpressing breast cancer. Ther Adv Med Oncol 2012;4:139-47. [PMID: 22590487 DOI: 10.1177/1758834012440834] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
243 van Hasselt JG, Schellens JH, Mac Gillavry MR, Beijnen JH, Huitema AD. Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab. Pharm Res 2012;29:3499-511. [PMID: 22907417 DOI: 10.1007/s11095-012-0845-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
244 Tina E, Lindqvist BM, Gabrielson M, Lubovac Z, Wegman P, Wingren S. The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors. BMC Cancer 2012;12:350. [PMID: 22883974 DOI: 10.1186/1471-2407-12-350] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
245 Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkäs K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Bégin LR, van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012;107:800-7. [PMID: 22850554 DOI: 10.1038/bjc.2012.338] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 11.1] [Reference Citation Analysis]
246 Aogi K, Saeki T, Nakamura S, Kashiwaba M, Sato N, Masuda N, Rai Y, Ohno S, Kuroi K, Nishimura R, Miyakoda K, Akiyama F, Kurosumi M, Ikeda T. A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study). Int J Clin Oncol 2013;18:598-606. [PMID: 22833344 DOI: 10.1007/s10147-012-0437-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
247 Munk M, Memon AA, Goetze JP, Nielsen LB, Nexo E, Sorensen BS. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes. PLoS One 2012;7:e40243. [PMID: 22792252 DOI: 10.1371/journal.pone.0040243] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
248 Sekaran A, Kandagaddala RS, Darisetty S, Lakhtakia S, Ayyagari S, Rao GV, Rebala P, Reddy DB, Reddy DN. HER2 expression in gastric cancer in Indian population--an immunohistochemistry and fluorescence in situ hybridization study. Indian J Gastroenterol. 2012;31:106-110. [PMID: 22760626 DOI: 10.1007/s12664-012-0214-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
249 Mehta AI, Brufsky AM, Sampson JH. Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier. Cancer Treat Rev 2013;39:261-9. [PMID: 22727691 DOI: 10.1016/j.ctrv.2012.05.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
250 Bilous M, Morey AL, Armes JE, Bell R, Button PH, Cummings MC, Fox SB, Francis GD, Waite B, McCue G, Raymond WA, Robbins PD, Farshid G. Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. Breast Cancer Res Treat 2012;134:617-24. [PMID: 22678156 DOI: 10.1007/s10549-012-2093-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
251 Oliva S, Cioffi G, Frattini S, Simoncini EL, Faggiano P, Boccardi L, Pulignano G, Fioretti AM, Giotta F, Lestuzzi C, Maurea N, Sabatini S, Tarantini L; Italian Cardio-Oncological Network. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world? Oncologist 2012;17:917-24. [PMID: 22673631 DOI: 10.1634/theoncologist.2011-0445] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
252 Armstrong AC, Gilham DE. Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein? Breast Cancer Res 2012;14:106. [PMID: 22643384 DOI: 10.1186/bcr3184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
253 Wong FY, Yip CS, Chua ET. Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ? World J Surg 2012;36:287-94. [PMID: 22105650 DOI: 10.1007/s00268-011-1353-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
254 Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V. Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial. ISRN Oncol 2012;2012:176789. [PMID: 22666610 DOI: 10.5402/2012/176789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
255 Váradi T, Mersich T, Auvinen P, Tammi R, Tammi M, Salamon F, Besznyák I Jr, Jakab F, Baranyai Z, Szöllősi J, Nagy P. Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan. J Histochem Cytochem 2012;60:567-75. [PMID: 22562558 DOI: 10.1369/0022155412448070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
256 Waterhouse BR, Gijsen M, Barber PR, Tullis ID, Vojnovic B, Kong A. Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. Oncotarget 2011;2:728-36. [PMID: 21908901 DOI: 10.18632/oncotarget.313] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
257 Gori S, Clavarezza M, Siena S, Foglietta J, Tarenzi E, Giordano M, Molino A, Graiff C, Fusco V, Alabiso O, Baldini E, Gamucci T, Altavilla G, Dondi D, Venturini M. Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. BMC Cancer 2012;12:158. [PMID: 22545982 DOI: 10.1186/1471-2407-12-158] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
258 Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, D’Amico R. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243. [PMID: 22513938 DOI: 10.1002/14651858.cd006243.pub2] [Cited by in Crossref: 113] [Cited by in F6Publishing: 165] [Article Influence: 11.3] [Reference Citation Analysis]
259 Li Y, Shi L, Han C, Wang Y, Yang J, Cao C, Jiao S. Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells. Tumour Biol 2012;33:1403-10. [PMID: 22528939 DOI: 10.1007/s13277-012-0388-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
260 Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48-54. [PMID: 22012633 DOI: 10.1007/s11912-011-0203-y] [Cited by in Crossref: 528] [Cited by in F6Publishing: 472] [Article Influence: 52.8] [Reference Citation Analysis]
261 Syed Alwi SS, Cavell BE, Donlevy A, Packham G. Differential induction of apoptosis in human breast cancer cell lines by phenethyl isothiocyanate, a glutathione depleting agent. Cell Stress Chaperones 2012;17:529-38. [PMID: 22351438 DOI: 10.1007/s12192-012-0329-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
262 Li J, Chen F, Cona MM, Feng Y, Himmelreich U, Oyen R, Verbruggen A, Ni Y. A review on various targeted anticancer therapies. Target Oncol 2012;7:69-85. [PMID: 22350489 DOI: 10.1007/s11523-012-0212-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 4.9] [Reference Citation Analysis]
263 Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012;122:1066-75. [PMID: 22326955 DOI: 10.1172/JCI61226] [Cited by in Crossref: 169] [Cited by in F6Publishing: 104] [Article Influence: 16.9] [Reference Citation Analysis]
264 Wesolowski R, Ramaswamy B. Gene expression profiling: changing face of breast cancer classification and management. Gene Expr. 2011;15:105-115. [PMID: 22268293 DOI: 10.3727/105221611x13176664479241] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
265 Yoong J, Michael M, Leong T. Targeted therapies for gastric cancer: current status. Drugs. 2011;71:1367-1384. [PMID: 21812503 DOI: 10.2165/11592530-000000000-00000] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
266 Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012;379:633-640. [PMID: 22257673 DOI: 10.1016/s0140-6736(11)61847-3] [Cited by in Crossref: 853] [Cited by in F6Publishing: 386] [Article Influence: 85.3] [Reference Citation Analysis]
267 Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012;22:3-13. [PMID: 22245472 DOI: 10.1016/j.semcancer.2011.12.009] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 9.9] [Reference Citation Analysis]
268 Howe LR, Brown PH. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila) 2011;4:1149-57. [PMID: 21816844 DOI: 10.1158/1940-6207.CAPR-11-0334] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
269 Monte AA, Vasiliou V, Heard KJ. Omics Screening for Pharmaceutical Efficacy and Safety in Clinical Practice. J Pharmacogenomics Pharmacoproteomics 2012;S5:001. [PMID: 23264882 DOI: 10.4172/2153-0645.s5-001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
270 Park K, Han S, Kim JY, Kim HJ, Kwon JE, Gwak G. Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer. J Breast Cancer 2011;14:276-82. [PMID: 22323913 DOI: 10.4048/jbc.2011.14.4.276] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
271 Amedei A, Benagiano M, della Bella C, Niccolai E, D'Elios MM. Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol 2011;2011:437348. [PMID: 22253528 DOI: 10.1155/2011/437348] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
272 Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011;9:16-32. [PMID: 22124364 DOI: 10.1038/nrclinonc.2011.177] [Cited by in Crossref: 531] [Cited by in F6Publishing: 493] [Article Influence: 48.3] [Reference Citation Analysis]
273 Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011;13:R121. [PMID: 22123186 DOI: 10.1186/bcr3067] [Cited by in Crossref: 158] [Cited by in F6Publishing: 154] [Article Influence: 14.4] [Reference Citation Analysis]
274 Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J, Li L, Jia W, Zhang Y, Liu W, Wei W, Xie X. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol 2012;138:275-84. [PMID: 22116318 DOI: 10.1007/s00432-011-1095-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
275 Ferrusi IL, Leighl NB, Kulin NA, Marshall DA. Do economic evaluations of targeted therapy provide support for decision makers? J Oncol Pract 2011;7:36s-45s. [PMID: 21886518 DOI: 10.1200/JOP.2011.000315] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
276 Hamm C, El-Masri M, Poliquin G, Poliquin V, Mathews J, Kanjeekal S, Alam Y, Kulkarni S, Elfiki T. A single-centre chart review exploring the adjusted association between breast cancer phenotype and prognosis. Curr Oncol 2011;18:191-6. [PMID: 21874118 DOI: 10.3747/co.v18i4.815] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
277 Somlo G, Martel CL, Lau SK, Frankel P, Ruel C, Gu L, Hurria A, Chung C, Luu T, Morgan R Jr, Leong L, Koczywas M, McNamara M, Russell CA, Kane SE. A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Res Treat 2012;131:899-906. [PMID: 22042372 DOI: 10.1007/s10549-011-1850-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
278 Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011;29:4491-4497. [PMID: 22042958 DOI: 10.1200/jco.2011.36.7045] [Cited by in Crossref: 185] [Cited by in F6Publishing: 80] [Article Influence: 16.8] [Reference Citation Analysis]
279 Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273-1283. [PMID: 21991949 DOI: 10.1056/nejmoa0910383] [Cited by in Crossref: 1540] [Cited by in F6Publishing: 716] [Article Influence: 140.0] [Reference Citation Analysis]
280 Bertos NR, Park M. Breast cancer - one term, many entities? J Clin Invest. 2011;121:3789-3796. [PMID: 21965335 DOI: 10.1172/jci57100] [Cited by in Crossref: 133] [Cited by in F6Publishing: 79] [Article Influence: 12.1] [Reference Citation Analysis]
281 Zeng T, Gao H, Yu P, He H, Ouyang X, Deng L, Zhang Y. Up-regulation of kin17 is essential for proliferation of breast cancer. PLoS One 2011;6:e25343. [PMID: 21980430 DOI: 10.1371/journal.pone.0025343] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
282 Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer 2011;105:1273-8. [PMID: 21959871 DOI: 10.1038/bjc.2011.390] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
283 Mukohara T. Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer. Chemother Res Pract 2011;2011:730360. [PMID: 22295205 DOI: 10.1155/2011/730360] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
284 Abdel-Razeq H, Marei L. Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics 2011;5:87-94. [PMID: 21847344 DOI: 10.2147/BTT.S22917] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
285 Sagara Y, Kamada Y, Yamamoto Y, Tanaka M, Kubo M, Yamaguchi R, Nishimura R, Mitsuyama S. Study on the state of implementation of HER2 testing and positive ratios in patients with breast cancer in the Kyushu-Okinawa region of Japan. Breast Cancer 2012;19:315-20. [PMID: 21814842 DOI: 10.1007/s12282-011-0295-0] [Reference Citation Analysis]
286 Kemp Z, Jones A. A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer. Adv Ther 2011;28:603-14. [PMID: 21833702 DOI: 10.1007/s12325-011-0050-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
287 Pituskin E, Haykowsky M, Mackey JR, Thompson RB, Ezekowitz J, Koshman S, Oudit G, Chow K, Pagano JJ, Paterson I. Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. BMC Cancer 2011;11:318. [PMID: 21794114 DOI: 10.1186/1471-2407-11-318] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
288 Minami CA, Chung DU, Chang HR. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011;5:175-99. [PMID: 21863131 DOI: 10.4137/BCBCR.S6562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 0.7] [Reference Citation Analysis]
289 Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE, Martino S, Mamounas EP, Kaufman PA, Wolmark N. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 2011;29:3366-3373. [PMID: 21768458 DOI: 10.1200/jco.2011.35.0868] [Cited by in Crossref: 493] [Cited by in F6Publishing: 222] [Article Influence: 44.8] [Reference Citation Analysis]
290 Goel AK, Nandy M, Sharma G. Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results. Indian J Med Paediatr Oncol 2010;31:76-8. [PMID: 21206711 DOI: 10.4103/0971-5851.73588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
291 Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol 2008;15:S16-29. [PMID: 18231644 DOI: 10.3747/co.2008.173] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
292 Verma S, Lavasani S, Mackey J, Pritchard K, Clemons M, Dent S, Latreille J, Lemieux J, Provencher L, Verma Sh, Chia S, Wang B, Rayson D. Optimizing the management of HER2-positive early breast cancer: the clinical reality. Curr Oncol 2010;17:20-33. [PMID: 20697511 DOI: 10.3747/co.v17i4.700] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
293 Yin W, Jiang Y, Shen Z, Shao Z, Lu J. Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials. PLoS One 2011;6:e21030. [PMID: 21695277 DOI: 10.1371/journal.pone.0021030] [Cited by in Crossref: 125] [Cited by in F6Publishing: 106] [Article Influence: 11.4] [Reference Citation Analysis]
294 Manion E, Hornick JL, Lester SC, Brock JE. A comparison of equivocal immunohistochemical results with anti-HER2/neu antibodies A0485 and SP3 with corresponding FISH results in routine clinical practice. Am J Clin Pathol 2011;135:845-51. [PMID: 21571957 DOI: 10.1309/AJCPIP5LOO3NGDJG] [Cited by in Crossref: 21] [Cited by in F6Publishing: 5] [Article Influence: 1.9] [Reference Citation Analysis]
295 Boekhout AH, Beijnen JH, Schellens JH. Trastuzumab. Oncologist 2011;16:800-10. [PMID: 21632460 DOI: 10.1634/theoncologist.2010-0035] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.9] [Reference Citation Analysis]
296 Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Ménétrier-Caux C, Trédan O, Goddard-Léon S, Pin JJ, Mignotte H, Bathélémy-Dubois C, Caux C, Lebecque S, Blay JY. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. BMC Cancer 2011;11:213. [PMID: 21624121 DOI: 10.1186/1471-2407-11-213] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
297 Sautter-Bihl ML, Souchon R, Gerber B. Adjuvant therapy for women over age 65 with breast cancer. Dtsch Arztebl Int 2011;108:365-71. [PMID: 21691560 DOI: 10.3238/arztebl.2011.0365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
298 Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J, Zizzari IG, Ruscito I, Rahimi H, Benedetti-Panici P, Rughetti A. Immune effects of trastuzumab. J Cancer 2011;2:317-23. [PMID: 21716848 DOI: 10.7150/jca.2.317] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
299 Garrett JT, Arteaga CL. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther. 2011;11:793-800. [PMID: 21307659 DOI: 10.4161/cbt.11.9.15045] [Cited by in Crossref: 121] [Cited by in F6Publishing: 111] [Article Influence: 11.0] [Reference Citation Analysis]
300 Purmonen TT, Pänkäläinen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol 2011;50:344-52. [PMID: 21299447 DOI: 10.3109/0284186X.2011.553841] [Cited by in Crossref: 33] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
301 Shigematsu H, Kawaguchi H, Nakamura Y, Tanaka K, Shiotani S, Koga C, Nishimura S, Taguchi K, Nishiyama K, Ohno S. Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000. BMC Cancer 2011;11:118. [PMID: 21453503 DOI: 10.1186/1471-2407-11-118] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
302 Patil VW, Singhai R, Patil AV, Gurav PD. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Cancer (Dove Med Press). 2011;3:9-19. [PMID: 24367172 DOI: 10.2147/bctt.s17094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
303 Komarova TV, Kosorukov VS, Frolova OY, Petrunia IV, Skrypnik KA, Gleba YY, Dorokhov YL. Plant-made trastuzumab (herceptin) inhibits HER2/Neu+ cell proliferation and retards tumor growth. PLoS One 2011;6:e17541. [PMID: 21390232 DOI: 10.1371/journal.pone.0017541] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
304 Sanpaolo P, Barbieri V, Pedicini P, Fusco V. Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis. Med Oncol 2012;29:459-65. [PMID: 21359639 DOI: 10.1007/s12032-011-9869-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
305 Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A 2011;108:3761-6. [PMID: 21321214 DOI: 10.1073/pnas.1014835108] [Cited by in Crossref: 195] [Cited by in F6Publishing: 186] [Article Influence: 17.7] [Reference Citation Analysis]
306 Lamy PJ, Fina F, Bascoul-Mollevi C, Laberenne AC, Martin PM, Ouafik L, Jacot W. Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. Breast Cancer Res 2011;13:R15. [PMID: 21288332 DOI: 10.1186/bcr2824] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
307 Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011;135:55-62. [PMID: 21204711 DOI: 10.5858/2010-0454-RAR.1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 129] [Article Influence: 7.3] [Reference Citation Analysis]
308 Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135:55-62. [PMID: 21204711 DOI: 10.1043/2010-0454-rar.1] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
309 Abramson V, Arteaga CL. New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available. Clin Cancer Res 2011;17:952-8. [PMID: 21248299 DOI: 10.1158/1078-0432.CCR-09-1947] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
310 Hayashi N, Nakamura S, Yagata H, Shimoda Y, Ota H, Hortobagyi GN, Cristofanilli M, Ueno NT. Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. Int J Clin Oncol 2011;16:596-600. [PMID: 21210173 DOI: 10.1007/s10147-010-0173-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
311 Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-50. [PMID: 21050974 DOI: 10.1016/j.jacc.2010.07.023] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 8.9] [Reference Citation Analysis]
312 Mantia-Smaldone GM, Edwards RP, Vlad AM. Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies. Cancer Manag Res 2011;3:25-38. [PMID: 21734812 DOI: 10.2147/CMR.S8759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 31] [Article Influence: 0.4] [Reference Citation Analysis]
313 Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011;11:59-67. [PMID: 21160526 DOI: 10.1038/nrc2966] [Cited by in Crossref: 551] [Cited by in F6Publishing: 522] [Article Influence: 45.9] [Reference Citation Analysis]
314 Chan OT, Chen ZM, Chung F, Kawachi K, Phan DC, Himmelfarb E, Lin F, Perry A, Wang HL. Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. Am J Clin Pathol 2010;134:880-5. [PMID: 21088150 DOI: 10.1309/AJCPK6QHNNOEMJIM] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
315 Holstege H, Horlings HM, Velds A, Langerød A, Børresen-Dale AL, van de Vijver MJ, Nederlof PM, Jonkers J. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010;10:654. [PMID: 21118481 DOI: 10.1186/1471-2407-10-654] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
316 Guiu S, Gauthier M, Coudert B, Bonnetain F, Favier L, Ladoire S, Tixier H, Guiu B, Penault-Llorca F, Ettore F, Fumoleau P, Arnould L. Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer 2010;103:1335-42. [PMID: 20978512 DOI: 10.1038/sj.bjc.6605939] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
317 Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol 2011;28 Suppl 1:S129-34. [PMID: 21080107 DOI: 10.1007/s12032-010-9742-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
318 Tsoutsou PG, Belkacemi Y, Gligorov J, Kuten A, Boussen H, Bese N, Koukourakis MI. Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider. Oncologist. 2010;15:1169-1178. [PMID: 21041378 DOI: 10.1634/theoncologist.2010-0187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
319 McArthur HL, Hudis CA. Chemotherapy: Neoadjuvant trial design: time for a brave new world? Nat Rev Clin Oncol 2010;7:359-60. [PMID: 20592708 DOI: 10.1038/nrclinonc.2010.85] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
320 Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA. Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 2010;15:1043-9. [PMID: 20930097 DOI: 10.1634/theoncologist.2010-0036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
321 Ottini L, Capalbo C, Rizzolo P, Silvestri V, Bronte G, Rizzo S, Russo A. HER2-positive male breast cancer: an update. Breast Cancer (Dove Med Press) 2010;2:45-58. [PMID: 24367166 DOI: 10.2147/BCTT.S6519] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
322 Thierry B, Kurkuri M, Shi JY, Lwin LE, Palms D. Herceptin functionalized microfluidic polydimethylsiloxane devices for the capture of human epidermal growth factor receptor 2 positive circulating breast cancer cells. Biomicrofluidics 2010;4:32205. [PMID: 21045921 DOI: 10.1063/1.3480573] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
323 Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, Mori M, Heinrich MC, Deininger MW, Druker BJ, Loriaux MM. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010;70:6233-7. [PMID: 20670955 DOI: 10.1158/0008-5472.CAN-10-0429] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
324 Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys H, Cocquyt V. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium. Acta Clin Belg 2010;65:300-4. [PMID: 21128555 DOI: 10.1179/acb.2010.066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
325 Lantz E, Cunningham I, Higa GM. Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health 2010;1:155-71. [PMID: 21072285 DOI: 10.2147/ijwh.s5647] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
326 Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol 2010;134:303-11. [PMID: 20660336 DOI: 10.1309/AJCP3BZY4YAFNTRG] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
327 Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 2010;15:799-809. [PMID: 20671105 DOI: 10.1634/theoncologist.2009-0029] [Cited by in Crossref: 76] [Cited by in F6Publishing: 71] [Article Influence: 6.3] [Reference Citation Analysis]
328 Rüschoff J, Dietel M, Baretton G, Arbogast S, Walch A, Monges G, Chenard MP, Penault-Llorca F, Nagelmeier I, Schlake W. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457:299-307. [PMID: 20665045 DOI: 10.1007/s00428-010-0952-2] [Cited by in Crossref: 322] [Cited by in F6Publishing: 290] [Article Influence: 26.8] [Reference Citation Analysis]
329 Purdie CA, Baker L, Ashfield A, Chatterjee S, Jordan LB, Quinlan P, Adamson DJ, Dewar JA, Thompson AM. Increased mortality in HER2 positive, oestrogen receptor positive invasive breast cancer: a population-based study. Br J Cancer 2010;103:475-81. [PMID: 20664587 DOI: 10.1038/sj.bjc.6605799] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
330 Banerjee S, Cunningham D. Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. Clin Colorectal Cancer 2010;9 Suppl 1:S28-35. [PMID: 20630848 DOI: 10.3816/CCC.2010.s.004] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
331 Mukai H. Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol 2010;15:335-40. [PMID: 20632056 DOI: 10.1007/s10147-010-0107-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
332 Untch M. Targeted Therapy for Early and Locally Advanced Breast Cancer. Breast Care (Basel) 2010;5:144-52. [PMID: 20847827 DOI: 10.1159/000315047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
333 Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 2010;63:210-9. [PMID: 20203220 DOI: 10.1136/jcp.2009.062760] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
334 Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R. Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 2010;8:53. [PMID: 20529245 DOI: 10.1186/1479-5876-8-53] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
335 Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 2010;28:2982-8. [PMID: 20479410 DOI: 10.1200/JCO.2009.26.5900] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
336 Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson BA, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 2010;12:R25. [PMID: 20459607 DOI: 10.1186/bcr2568] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 8.3] [Reference Citation Analysis]
337 Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, Arribas J, Rosen N, Baselga J. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 2010;16:2688-95. [PMID: 20406840 DOI: 10.1158/1078-0432.CCR-09-3407] [Cited by in Crossref: 102] [Cited by in F6Publishing: 50] [Article Influence: 8.5] [Reference Citation Analysis]
338 Hicks DG, Janarthanan BR, Vardarajan R, Kulkarni SA, Khoury T, Dim D, Budd GT, Yoder BJ, Tubbs R, Schreeder MT, Estopinal NC, Beck RA, Wang Y, Ring BZ, Seitz RS, Ross DT. The expression of TRMT2A, a novel cell cycle regulated protein, identifies a subset of breast cancer patients with HER2 over-expression that are at an increased risk of recurrence. BMC Cancer 2010;10:108. [PMID: 20307320 DOI: 10.1186/1471-2407-10-108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
339 Petrelli F, Barni S. Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate. Med Oncol 2011;28:401-8. [PMID: 20195801 DOI: 10.1007/s12032-010-9460-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
340 Rydén L, Haglund M, Bendahl PO, Hatschek T, Kolaric A, Kovács A, Olsson A, Olsson H, Strand C, Fernö M; Swedish Her2 Analysis Group. Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol 2009;48:860-6. [PMID: 19353340 DOI: 10.1080/02841860902862511] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
341 Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010;28:1138-1144. [PMID: 20124182 DOI: 10.1200/jco.2009.24.2024] [Cited by in Crossref: 445] [Cited by in F6Publishing: 174] [Article Influence: 37.1] [Reference Citation Analysis]
342 Mackey JR, Clemons M, Côté MA, Delgado D, Dent S, Paterson A, Provencher L, Sawyer MB, Verma S. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008;15:24-35. [PMID: 18317582 DOI: 10.3747/co.2008.199] [Cited by in Crossref: 106] [Cited by in F6Publishing: 85] [Article Influence: 8.8] [Reference Citation Analysis]
343 Verma S. Trastuzumab in the adjuvant setting: concurrent or sequential? It takes two to tango! Curr Oncol 2008;15:66-7. [PMID: 18317588 DOI: 10.3747/co.2008.204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
344 Seal MD, Chia SK. Challenging the dogma on trastuzumab: a matter of the heart. The Lancet 2010;375:349-50. [DOI: 10.1016/s0140-6736(09)62069-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
345 Bese NS, Umay C, Serdengecti S, Kepil N, Sut N, Altug T, Ober A. The impact of trastuzumab on radiation-induced pulmonary fibrosis: results of an experimental study. Med Oncol 2010;27:1415-9. [PMID: 20041318 DOI: 10.1007/s12032-009-9395-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
346 Johnston SR. Are current drug development programmes realising the full potential of new agents? The scenario. Breast Cancer Res 2009;11 Suppl 3:S21. [PMID: 20030873 DOI: 10.1186/bcr2440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
347 Pirmohamed M. The applications of pharmacogenetics to prescribing: what is currently practicable? Clin Med (Lond) 2009;9:493-5. [PMID: 19886116 DOI: 10.7861/clinmedicine.9-5-493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
348 Morris PG, Dickler M, McArthur HL, Traina T, Sugarman S, Lin N, Moy B, Come S, Godfrey L, Nulsen B, Chen C, Steingart R, Rugo H, Norton L, Winer E, Hudis CA, Dang CT. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol 2009;27:6117-23. [PMID: 19901120 DOI: 10.1200/JCO.2008.20.2952] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
349 Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010;21:815-9. [PMID: 19889613 DOI: 10.1093/annonc/mdp488] [Cited by in Crossref: 132] [Cited by in F6Publishing: 115] [Article Influence: 10.2] [Reference Citation Analysis]
350 Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 2009;101:1453-63. [PMID: 19855077 DOI: 10.1093/jnci/djp334] [Cited by in Crossref: 82] [Cited by in F6Publishing: 64] [Article Influence: 6.3] [Reference Citation Analysis]
351 Pritchard KI. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era? Oncologist 2009;14:959-62. [PMID: 19819915 DOI: 10.1634/theoncologist.2009-0219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
352 Penault-Llorca F, Bilous M, Dowsett M, Hanna W, Osamura RY, Rüschoff J, van de Vijver M. Emerging technologies for assessing HER2 amplification. Am J Clin Pathol 2009;132:539-48. [PMID: 19762531 DOI: 10.1309/AJCPV2I0HGPMGBSQ] [Cited by in Crossref: 105] [Cited by in F6Publishing: 29] [Article Influence: 8.1] [Reference Citation Analysis]
353 Kelleher MT, Fruhwirth G, Patel G, Ofo E, Festy F, Barber PR, Ameer-Beg SM, Vojnovic B, Gillett C, Coolen A, Kéri G, Ellis PA, Ng T. The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. Target Oncol 2009;4:235-52. [PMID: 19756916 DOI: 10.1007/s11523-009-0116-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
354 Mayer IA. Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer 2009;9 Suppl 2:S50-7. [PMID: 19596643 DOI: 10.3816/CBC.2009.s.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
355 Chung C, Stuart D, Keyes M. Radiation recall reaction induced by adjuvant trastuzumab (herceptin). Case Rep Med 2009;2009:307894. [PMID: 19746202 DOI: 10.1155/2009/307894] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
356 Tan P. Divide and conquer: progress in the molecular stratification of cancer. Yonsei Med J 2009;50:464-73. [PMID: 19718393 DOI: 10.3349/ymj.2009.50.4.464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
357 Montejo M, Werner TL, Gaffney D. Current challenges in clinical management of endometrial cancer. Adv Drug Deliv Rev 2009;61:883-9. [PMID: 19422864 DOI: 10.1016/j.addr.2009.04.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
358 Abair T, Peck S, O'shaughnessy JA. Highlights From: The 2009 Annual Meeting of the American Society of Clinical Oncology. Clinical Breast Cancer 2009;9:140-4. [DOI: 10.3816/cbc.2009.023] [Reference Citation Analysis]
359 Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 2009;158:294-301. [PMID: 19619708 DOI: 10.1016/j.ahj.2009.05.031] [Cited by in Crossref: 165] [Cited by in F6Publishing: 137] [Article Influence: 12.7] [Reference Citation Analysis]
360 Fiúza M. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer. Adv Ther 2009;26 Suppl 1:S9-17. [PMID: 19669637 DOI: 10.1007/s12325-009-0048-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
361 Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75. [DOI: 10.1038/nrc2656] [Cited by in Crossref: 782] [Cited by in F6Publishing: 723] [Article Influence: 60.2] [Reference Citation Analysis]
362 Wishart GC, Greenberg DC, Chou P, Brown CH, Duffy S, Purushotham AD. Treatment and survival in breast cancer in the Eastern Region of England. Ann Oncol 2010;21:291-6. [PMID: 19502647 DOI: 10.1093/annonc/mdp301] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
363 Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group., TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:1681-92. [PMID: 19447249 DOI: 10.1016/S0140-6736(09)60740-6] [Cited by in Crossref: 133] [Cited by in F6Publishing: 50] [Article Influence: 10.2] [Reference Citation Analysis]
364 Britten CD, Finn RS, Bosserman LD, Wong SG, Press MF, Malik M, Lum BL, Slamon DJ. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clin Breast Cancer 2009;9:16-22. [PMID: 19299235 DOI: 10.3816/CBC.2009.n.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
365 Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A 2009;106:8695-700. [PMID: 19433805 DOI: 10.1073/pnas.0903233106] [Cited by in Crossref: 78] [Cited by in F6Publishing: 75] [Article Influence: 6.0] [Reference Citation Analysis]
366 Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. J Oncol 2009;2009:567486. [PMID: 19424511 DOI: 10.1155/2009/567486] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 5.7] [Reference Citation Analysis]
367 Anderson BO, Jakesz R. Breast cancer issues in developing countries: an overview of the Breast Health Global Initiative. World J Surg 2008;32:2578-85. [PMID: 18283512 DOI: 10.1007/s00268-007-9454-z] [Cited by in Crossref: 181] [Cited by in F6Publishing: 96] [Article Influence: 13.9] [Reference Citation Analysis]
368 Flynn JF, Wong C, Wu JM. Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer. J Oncol 2009;2009:526963. [PMID: 19390622 DOI: 10.1155/2009/526963] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
369 Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009;27:2962-9. [PMID: 19364966 DOI: 10.1200/JCO.2008.19.7939] [Cited by in Crossref: 131] [Cited by in F6Publishing: 49] [Article Influence: 10.1] [Reference Citation Analysis]
370 Leung M, Shapira I, Bradley T, Budman DR. Adjuvant chemotherapy for early breast cancer in the elderly. Curr Treat Options Oncol 2009;10:144-58. [PMID: 19360475 DOI: 10.1007/s11864-009-0092-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
371 Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009;100:684-92. [PMID: 19259090 DOI: 10.1038/sj.bjc.6604909] [Cited by in Crossref: 155] [Cited by in F6Publishing: 125] [Article Influence: 11.9] [Reference Citation Analysis]
372 Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009;27:2638-44. [PMID: 19349549 DOI: 10.1200/JCO.2008.17.9549] [Cited by in Crossref: 134] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
373 López-Tarruella S, Martín M. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 2009;11:204. [PMID: 19344489 DOI: 10.1186/bcr2226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
374 Tripathy D. HER2 status and breast cancer therapy: recent advances. F1000 Med Rep 2009;1:20. [PMID: 20948761 DOI: 10.3410/M1-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
375 Van Vlaenderen I, Canon JL, Cocquyt V, Jerusalem G, Machiels JP, Neven P, Nechelput M, Delabaye I, Gyldmark M, Annemans L. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clin Belg 2009;64:100-12. [PMID: 19432022 DOI: 10.1179/acb.2009.019] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
376 Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 2009;11:R9. [PMID: 19228416 DOI: 10.1186/bcr2225] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 4.5] [Reference Citation Analysis]
377 Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer 2009;100:680-3. [PMID: 19223897 DOI: 10.1038/sj.bjc.6604940] [Cited by in Crossref: 66] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
378 Park YH. Drug Therapy for Breast Cancer. J Korean Med Assoc 2009;52:963. [DOI: 10.5124/jkma.2009.52.10.963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
379 Agostara B, Carruba G, Usset A. The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing 2008;5:16. [PMID: 19116012 DOI: 10.1186/1742-4933-5-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
380 Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, Iwase H, Fujii Y. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer. 2008;8:309. [PMID: 18950515 DOI: 10.1186/1471-2407-8-309] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
381 Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, Park IA, Noh DY, Bang YJ, Kim TY. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008;8:307. [PMID: 18947390 DOI: 10.1186/1471-2407-8-307] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 6.0] [Reference Citation Analysis]
382 Zhang T, Herlyn D. Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother. 2009;58:475-492. [PMID: 18925393 DOI: 10.1007/s00262-008-0598-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
383 Koutras AK, Evans TR. The epidermal growth factor receptor family in breast cancer. Onco Targets Ther 2008;1:5-19. [PMID: 21127748 DOI: 10.2147/ott.s3842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
384 Qin J, Jones RC, Ramakrishnan R. Studying copy number variations using a nanofluidic platform. Nucleic Acids Res 2008;36:e116. [PMID: 18710881 DOI: 10.1093/nar/gkn518] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 5.7] [Reference Citation Analysis]
385 Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 2008;13:295-308. [PMID: 18537522 DOI: 10.1517/14728214.13.2.295] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
386 Mackenzie R, Chapman S, Salkeld G, Holding S. Media influence on Herceptin subsidization in Australia: application of the rule of rescue? J R Soc Med 2008;101:305-12. [PMID: 18515778 DOI: 10.1258/jrsm.2008.070289] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
387 Turner NC, Jones AL. Management of breast cancer--Part II. BMJ 2008;337:a540. [PMID: 18621762 DOI: 10.1136/bmj.a540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
388 Koh E, Do V, Barton M. Frontiers of cancer care in Asia-Pacific region: cancer care in Australia. Biomed Imaging Interv J 2008;4:e30. [PMID: 21611000 DOI: 10.2349/biij.4.3.e30] [Reference Citation Analysis]
389 Offersen BV, Alsner J, Ege Olsen K, Riisbro R, Brünner N, Sørensen FB, Sørensen BS, Schlemmer BO, Overgaard J. A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer. Acta Oncol 2008;47:618-32. [PMID: 18465330 DOI: 10.1080/02841860801958295] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
390 Pocock SJ, Travison TG, Wruck LM. How to interpret figures in reports of clinical trials. BMJ 2008;336:1166-9. [PMID: 18497415 DOI: 10.1136/bmj.39561.548924.94] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
391 Tuynman JB, Lagarde SM, Ten Kate FJ, Richel DJ, van Lanschot JJ. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008;98:1102-8. [PMID: 18349821 DOI: 10.1038/sj.bjc.6604251] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
392 Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat. 2009;113:501-507. [PMID: 18327638 DOI: 10.1007/s10549-008-9951-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
393 Anderson BO, Jakesz R. Breast Cancer Issues in Developing Countries: An Overview of the Breast Health Global Initiative. World J Surg 2008;32:2578-85. [DOI: 10.1007/s00268-007-9454-z] [Cited by in Crossref: 100] [Cited by in F6Publishing: 77] [Article Influence: 7.1] [Reference Citation Analysis]
394 Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, Gralow JR, Dakhil SR, Ingle JN. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231-1238. [PMID: 18250349 DOI: 10.1200/jco.2007.13.5467] [Cited by in Crossref: 361] [Cited by in F6Publishing: 152] [Article Influence: 25.8] [Reference Citation Analysis]
395 Dahl O, Borkamo ED, Fluge O. Current status of antivascular therapy and targeted treatment in the clinic. Int J Hyperthermia 2008;24:97-110. [PMID: 18214773 DOI: 10.1080/02656730701824406] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
396 Wu Y, Mohamed H, Chillar R, Ali I, Clayton S, Slamon D, Vadgama JV. Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer. Breast Cancer Res 2008;10:R3. [PMID: 18184439 DOI: 10.1186/bcr1844] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
397 Chalkidou K, Hoy A, Littlejohns P. Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. J R Soc Med 2007;100:453-60. [PMID: 17911127 DOI: 10.1177/014107680710001013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
398 Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O'Hare T, Heinrich MC, Deininger MW, Druker BJ. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 2008;111:2238-45. [PMID: 18025156 DOI: 10.1182/blood-2007-06-097253] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
399 Regan MM, Gelber RD; International Breast Cancer Study Group (IBCSG) and the Breast International Group (BIG). Using clinical trial data to tailor adjuvant treatments for individual patients. Breast 2007;16 Suppl 2:S98-104. [PMID: 17719227 DOI: 10.1016/j.breast.2007.07.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
400 Tripathy D, Tripathy D. 2007 Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL, June 2007. Clinical Breast Cancer 2007;7:660-9. [DOI: 10.1016/s1526-8209(11)70766-2] [Reference Citation Analysis]
401 Karnon J, Kerr GR, Jack W, Papo NL, Cameron DA. Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis. Br J Cancer 2007;97:479-85. [PMID: 17653077 DOI: 10.1038/sj.bjc.6603887] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
402 Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369:1742-57. [PMID: 17512859 DOI: 10.1016/S0140-6736(07)60781-8] [Cited by in Crossref: 475] [Cited by in F6Publishing: 274] [Article Influence: 31.7] [Reference Citation Analysis]
403 Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145. [PMID: 17159189 DOI: 10.5858/arpa.2013-0953-sa] [Cited by in Crossref: 612] [Cited by in F6Publishing: 311] [Article Influence: 38.3] [Reference Citation Analysis]